Abbott Laboratories, FCFF calculation

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net earnings	5,723)	6,933)	7,071)	4,495)	3,687)
Net noncash charges	4,013)	4,167)	4,233)	4,298)	3,780)
(Increase) decrease in operating capital	(2,475)	(1,519)	(771)	(892)	(1,331)
Net cash from operating activities	7,261)	9,581)	10,533)	7,901)	6,136)
Interest paid, net of tax¹	569)	470)	468)	497)	598)
Acquisitions of property and equipment	(2,202)	(1,777)	(1,885)	(2,177)	(1,638)
Free cash flow to the firm (FCFF)	5,628)	8,274)	9,116)	6,221)	5,096)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ See details »

Download chart

Item	Description	The company
FCFF	Free cash flow to the firm is the cash flow available to the Abbott Laboratories suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made.	Abbott Laboratories FCFF decreased from 2021 to 2022 and from 2022 to 2023.

Abbott Laboratories, interest paid, net of tax calculation

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Effective Income Tax Rate (EITR)
EITR¹	14.10%	16.50%	13.90%	9.50%	11.70%
Interest Paid, Net of Tax
Interest paid, before tax	662)	563)	544)	549)	677)
Less: Interest paid, tax²	93)	93)	76)	52)	79)
Interest paid, net of tax	569)	470)	468)	497)	598)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ See details »

² 2023 Calculation
Interest paid, tax = Interest paid × EITR
= 662 × 14.10% = 93

Download chart

Abbott Laboratories, current EV/FCFF calculation, comparison to benchmarks

Selected Financial Data (US$ in millions)
Enterprise value (EV)	210,781)
Free cash flow to the firm (FCFF)	5,628)
Valuation Ratio
EV/FCFF	37.45
Benchmarks
EV/FCFF, Competitors¹
Cigna Group	9.70
CVS Health Corp.	9.87
Elevance Health Inc.	10.61
Humana Inc.	6.95
Intuitive Surgical Inc.	249.18
Medtronic PLC	21.64
UnitedHealth Group Inc.	20.14
EV/FCFF, Sector
Health Care Equipment & Services	19.21
EV/FCFF, Industry
Health Care	23.67

Based on: 10-K (reporting date: 2023-12-31).

¹ Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.

Abbott Laboratories, historical EV/FCFF calculation, comparison to benchmarks

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selected Financial Data (US$ in millions)
Enterprise value (EV)¹	205,452)	192,330)	213,980)	229,787)	168,424)
Free cash flow to the firm (FCFF)²	5,628)	8,274)	9,116)	6,221)	5,096)
Valuation Ratio
EV/FCFF³	36.51	23.24	23.47	36.94	33.05
Benchmarks
EV/FCFF, Competitors⁴
Cigna Group	10.44	13.38	14.17	9.16	10.24
CVS Health Corp.	11.96	10.00	10.30	9.42	12.30
Elevance Health Inc.	14.19	13.32	12.74	6.04	12.73
Humana Inc.	9.95	14.88	42.03	7.92	8.46
Intuitive Surgical Inc.	170.92	85.45	56.01	76.70	54.58
Medtronic PLC	26.54	20.32	33.84	21.43	22.07
UnitedHealth Group Inc.	17.59	19.30	22.21	15.82	17.51
EV/FCFF, Sector
Health Care Equipment & Services	18.44	17.28	19.60	14.85	16.66
EV/FCFF, Industry
Health Care	24.38	17.63	16.41	17.93	18.26

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ See details »

² See details »

³ 2023 Calculation
EV/FCFF = EV ÷ FCFF
= 205,452 ÷ 5,628 = 36.51

⁴ Click competitor name to see calculations.

Download chart

Valuation ratio	Description	The company
EV/FCFF	Enterprise value to free cash flow to the firm is whole company valuation indicator.	Abbott Laboratories EV/FCFF ratio decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.

Abbott Laboratories (NYSE:ABT)

Enterprise Value to FCFF (EV/FCFF)

Free Cash Flow to The Firm (FCFF)

Interest Paid, Net of Tax

Enterprise Value to FCFF Ratio, Current

Enterprise Value to FCFF Ratio, Historical